Literature DB >> 8375935

In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines.

L Zeng1, A Buard, I Monnet, C Boutin, J Fleury, L Saint-Etienne, P Brochard, J Bignon, M C Jaurand.   

Abstract

Malignant mesothelioma is a tumor arising from serous surfaces and often related to asbestos exposure. Malignant mesothelioma is resistant to various forms of therapy. Radiotherapy, surgery or chemotherapy only slightly improve prognosis. IFN-gamma produces complete or partial responses in stage-I patients with malignant mesothelioma. The in vitro biological effect of IFN-gamma on malignant mesothelioma cells remains poorly elucidated. In the present study, 32 well-characterized human mesothelioma cell lines (HMCL) were treated with r-hu IFN-gamma at 4 doses and cell growth was determined by a colorimetric method (MTT assay). Among the 32 HMCLs tested, II exhibited significant cell-growth inhibition; 16 were insensitive to r-hu IFN-gamma, and 5 were slightly inhibited. The sensitive cell lines were strongly inhibited by r-hu IFN-gamma. Our results show that HMCL exhibit a large range of responses to r-hu IFN-gamma, some of which can be compared with those obtained in vivo in humans.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8375935     DOI: 10.1002/ijc.2910550331

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

Review 1.  Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches.

Authors:  J W Upham; M J Garlepp; A W Musk; B W Robinson
Journal:  Thorax       Date:  1995-08       Impact factor: 9.139

2.  Signal transducer and activator of transcription 1 (STAT1) acts like an oncogene in malignant pleural mesothelioma.

Authors:  Lisa Arzt; Hannelore Kothmaier; Iris Halbwedl; Franz Quehenberger; Helmut H Popper
Journal:  Virchows Arch       Date:  2014-05-17       Impact factor: 4.064

3.  High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma.

Authors:  M Halme; A Knuuttila; T Vehmas; L Tammilehto; M Mäntylä; J Salo; K Mattson
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

4.  Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications.

Authors:  Yuna Blum; Clément Meiller; Lisa Quetel; Nabila Elarouci; Mira Ayadi; Danisa Tashtanbaeva; Lucile Armenoult; François Montagne; Robin Tranchant; Annie Renier; Leanne de Koning; Marie-Christine Copin; Paul Hofman; Véronique Hofman; Henri Porte; Françoise Le Pimpec-Barthes; Jessica Zucman-Rossi; Marie-Claude Jaurand; Aurélien de Reyniès; Didier Jean
Journal:  Nat Commun       Date:  2019-03-22       Impact factor: 14.919

5.  Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival.

Authors:  Lisa Quetel; Clément Meiller; Jean-Baptiste Assié; Yuna Blum; Sandrine Imbeaud; François Montagne; Robin Tranchant; Julien de Wolf; Stefano Caruso; Marie-Christine Copin; Véronique Hofman; Laure Gibault; Cécile Badoual; Ecaterina Pintilie; Paul Hofman; Isabelle Monnet; Arnaud Scherpereel; Françoise Le Pimpec-Barthes; Jessica Zucman-Rossi; Marie-Claude Jaurand; Didier Jean
Journal:  Mol Oncol       Date:  2020-03-10       Impact factor: 6.603

Review 6.  The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models.

Authors:  Christophe Blanquart; Marie-Claude Jaurand; Didier Jean
Journal:  Front Oncol       Date:  2020-03-25       Impact factor: 6.244

Review 7.  Use of preclinical models for malignant pleural mesothelioma.

Authors:  Marie Shamseddin; Joanna Obacz; Mathew J Garnett; Robert Campbell Rintoul; Hayley Elizabeth Francies; Stefan John Marciniak
Journal:  Thorax       Date:  2021-03-10       Impact factor: 9.139

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.